Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Starling OncologySTLN +5.56%56 PS Ratio is 0.93 as of Aug. 05, 2026, which is 90% above its 10-year median of 0.49. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Starling Oncology ranks better than 65.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Starling Oncology's share price is $5.17.
Starling Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $5.53. Hence, Starling Oncology's PS Ratio for today is 0.93.
The historical rank and industry rank for Starling Oncology's PS Ratio or its related term are showing as below:
STLN'
s PS Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.49 Max: 3.36
Current: 0.93
During the past 8 years, Starling Oncology's highest PS Ratio was 3.36. The lowest was 0.03. And the median was 0.49.
STLN's PS Ratio is ranked better than 65.14% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 1.51
vs STLN: 0.93
Starling Oncology Inc revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Starling Oncology was 4.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 15.60% per year.
During the past 8 years, Starling Oncology's highest 3-Year average Revenue per Share Growth Rate was 20.40% per year. The lowest was 9.10% per year. And the median was 19.60% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Starling Oncology PS Ratio Related Terms
Starling Oncology PS Ratio Historical Data
* Premium members only.
The historical data trend for Starling Oncology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Starling Oncology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starling Oncology PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Starling Oncology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Starling Oncology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Starling Oncology's Share Price of today is $5.17. Starling Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.53.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Starling Oncology (STLN) has a PS Ratio of 0.93 as of Aug. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Starling Oncology and its competitors. This is 90% above median its historical median of 0.49. Over the past decade, Starling Oncology's PS Ratio has ranged from 0.03 to 3.36. According to the industry distribution chart, Starling Oncology ranks #229 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 34.9%.
Is Starling Oncology's PS Ratio too high?
Starling Oncology's current PS Ratio of 0.93 is 90% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 3.36. The Healthcare Providers & Services industry median PS Ratio is 1.51. Starling Oncology's value of 0.93 is 38.4% below this industry median. Based on the distribution chart, Starling Oncology ranks #229 out of 657 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's PS Ratio compare to SRTA and CCRN?
According to the Healthcare Providers & Services industry distribution chart, Starling Oncology ranks #229 out of 657 companies for PS Ratio. This puts Starling Oncology in the upper half of its industry. The industry median PS Ratio is 1.51. Starling Oncology's value of 0.93 is 38.4% below this benchmark. Historically, Starling Oncology's own PS Ratio has ranged from 0.03 to 3.36 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 1.51, Starling Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.51, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starling Oncology's current PS Ratio of 0.93 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Starling Oncology and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starling Oncology's current PS Ratio is 0.93, which is 90% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current PS Ratio is 0.93, which is 90% above median its 10-year median of 0.49 and 38.4% below the Healthcare Providers & Services industry median of 1.51. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Starling Oncology (STLN), the current PS Ratio is 0.93 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starling Oncology (STLN) Overvalued in 2026?
Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued.
The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29.
GuruFocus considers Starling Oncology to be Significantly Overvalued.
Key valuation signals for STLN:
PS Ratio: 0.93 (90% above median its 10-year median of 0.49)
GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
Industry Position: 38.4% below the Healthcare Providers & Services median (#229 of 657)
No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score
Get the complete analysis for STLN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STLN has been successfully added to your 
